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Summary Cellular adhesion molecules have been implicated in tumour progression and metastasis. This study
examines for the first time the serum concentrations of circulating VCAM-1 and E-selectin in a consecutive
series of 110 cancer patients seen in a general medical oncology clinic, and confirms and extends previous
studies reporting measurement of circulating ICAM-1. Soluble ICAM-1 and VCAM-1 levels were significantly
higher in all the patient groups compared with the controls whereas soluble E-selectin was significantly higher
in the ovarian, breast and GI cancer groups and lower in the myeloma group. The significance of these results
together with the possible sources and stimuli for release of these adhesion molecules are discussed.
Cellular adhesion molecules mediating homotypic and
heterotypic cellular interactions have been implicated in the
various stages of tumour progression and metastasis (McCar-
thy et al., 1991). ICAM-1, the inducible ligand for lym-
phocyte function associated antigen-I (LFA-1) and Mac-i, is
found on endothelial cells, leukocytes and some epithelial
tissue (Smith & Thomas, 1990), and plays a major role in
cell-cell interactions in inflammatory and immune responses.
It has also been implicated in the progression of melanoma
(Natali et al., 1990). Recently the existence of a soluble
variant of ICAM-1 in the circulation has been described,
with elevated levels being reported in several diseases (Roth-
lein et al., 1991; Seth et al., 1991); higher levels being
associated with liver metastases in gastric, colonic, gall blad-
der and pancreatic cancers (Tsujisaki et al., 1991), and with
reduced survival in patients with malignant melanoma (Ham-
ing et al., 1991).
E-selectin (previously known as endothelial leukocyte
adhesion molecule-I or ELAM-1) is transiently expressed on
activated endothelial cells, mediating neutrophil, monocyte
and memory T cell adhesion. VCAM-1 is also induced on
endothelial cells, mediating adhesion of lymphocytes and
monocytes, but additionally is present on lymphoid dendritic
cells, some tissue macrophages and renal parietal epithelium
(Rice et al., 1991). Possible role for these molecules in metas-
tasis are suggested by the reports of VCAM-mediated
adhesion of melanoma cells (Rice & Bevilacqua 1989) and
E-selectin-mediated adhesion of colon carcinoma cells (Lauri
et al., 1991) to endothelium. Soluble variants of these
molecules in the circulation have recently been reported
(Gearing et al., 1992). The present study examines for the
first time the concentrations of VCAM-1 and E-selectin in
cancer patients and extends the number of cancers examined
with respect to circulating ICAM-1.
Materials and methods
Sera and patients
Blood samples were obtained from a consecutive series of all
patients being seen in a general medical oncology clinic,
including those with both localised or advanced disease and
those on active therapy or during follow-up. The following
malignancies were represented: bladder (n = 6), breast
(n = 13), gastrointestinal (n = 18), ovarian (n = 15), renal
(n = 12), Hodgkin's disease (n = 15), non-Hodgkin's lym-
phoma (n = 13), and myeloma (n = 18). Approximately 85%
of those with epithelial cancers had clinical evidence of
metastases. Samples were allowed to clot, and the serum
stored at - 70'C until assayed. Samples were also obtained
from 89 healthy laboratory and clinical personnel and blood
donors (age range 18-60 years) and assayed for E-selectin
and VCAM-1. In the case of ICAM-1, a sub-group of 27 of
the control samples (age range 24-54 years) were assayed.
Assay of soluble adhesion molecules
Levels of circulating ICAM-1 were measured with a commer-
cial ELISA kit (British Bio-technology Products, Oxford,
UK). Concentrations of circulating E-selectin and VCAM-1
were measured using dual monoclonal antibody two-site
ELISAs (Gearing et al., 1992; Pigott et al., 1992). Briefly,
microtitre ELISA plates (Nunc Immunoplates, Life Tech-
nologies, Paisley, Scotland) were coated overnight with a
specific capture antibody (BBIG-E2 for E-selectin, BBIG-V4
for VCAM-1) at a final concentration of 10 tg ml-' in 0.1 M
bicarbonate buffer pH 8.9. Standards and samples were
added to the plate, incubated for 2 h at room temperature
and the bound soluble adhesin of interest was detected by
sequential incubation with a specific biotin-labelled antibody
(BBIG-E5 for E-selectin, BBIG-V3 for VCAM-1) followed
by horseradish peroxidase-conjugated streptavidin (Amer-
sham International, Amersham, UK) and finally tetramethyl-
benzidine (Universal Biologicals, Kingston-upon-Thames,
UK). The reaction was stopped by the addition of 1 M HCI
to each well and the O.D. 450 nm measured using a Titertek
MS-2 reader (ICN Flow, Rickmansworth, UK). The assays
were standardised using a recombinant soluble form of E-
selectin or VCAM-1 (Pigott et al., 1991) lacking their trans-
membrane and cytoplasmic domains and given an arbitrary
unitage against which all samples were measured.
Statistical analysis
Data was analysed using SPSS/PC + . Results were not nor-
mally distributed when examined using the Lilliefors statistic
and normal plots, and accordingly were analysed using the
non-parametric Mann-Whitney test.
Results
Concentration of soluble E-selectin, VCAM-1 and ICAM-1
in the control and patient groups are shown in Figures la-c.
The median values (5th percentile, 95th percentile) for the
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a Table I Statistical significance of the concentrations of soluble
adhesion molecules in each patient group compared with the control
groups
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Patient group n E-selectin VCAM-J ICAM-1
Myeloma 18 P<0.05 P<0.01 P<0.01
NHL 13 NS P<0.0001 P<0.0001
HD 15 NS P<0.05 P<0.01
Ovarian 15 P<0.05 P<0.0001 P<0.0001
Breast 13 P<0.001 P<0.001 P<0.0001
GI 18 P<0.001 P<0001 P<0.0001
Renal 12 NS P<0.0001 P<0.0001
Bladder 6 NS P<0.001 P<0.001
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Figure la-c Measurement of soluble-E selectin a, VCAM-1 b,
and ICAM- I c, in sera from normal healthy controls and patients
with malignant diseases. The median values for each group are
shown by horizontal bars and dotted lines represent the 5th and
95th percentiles of the control groups.
soluble E-selectin, VCAM-1 and ICAM-1 concentrations of
the control groups were 8.0 U ml-' (4.3, 21.0; n = 89),
50.0 U ml-' (25.5, 156.5; n = 89) and 169.0 ng ml' (93.2,
291.8; n = 27) respectively. The statistical significances of the
comparisons between the control group and each of the
groups of cancer patients are shown in Table 1. Soluble
ICAM-1 and VCAM-1 levels were significantly higher in all
the patient groups compared with the controls whereas solu-
ble E-selection was significantly higher in the ovarian, breast
and GI groups and lower in the myeloma group.
Discussion
This is the first report of elevated levels of circulating E-
selectin and VCAM-1 in patients with cancer. The VCAM-1
concentrations were elevated in all cancer types studied and
E-selectin was elevated in three of the cancer types but
reduced in myeloma. We also confirm and extend earlier
reports of elevated soluble ICAM-1 in cancer patients (Tsu-jisaki et al., 1991; Harning et al., 1991). Interpretation of the
clinical and biological significance of these elevated levels is
complicated by the fact that in mixed groups such as these,
patients have varying stages of disease and some are on
active chemotherapy or biological therapy. Interleukin 2
therapy, for example, leads to the induction of circulating
ICAM-1 in melanoma patients (Becker et al., 1992). However
these preliminary observations provide the foundations for
future longitudinal and cross-sectional studies of the effects
of stage and treatment. These increases in circulating
adhesion molecule levels are unlikely to just reflect an under-
lying non-specific inflammatory response as, although similar
results for VCAM levels were obtained using samples from
patients with inflammatory bowel disease, no significant
elevation was seen in E-selectin levels and changes in
ICAM-1 levels were much less marked than those seen in the
patients with cancer (results not shown).
The significance of two of the normal healthy controls
having concentrations of VCAM> 1000 U ml-' is unknown
but is unlikely to be due to assay interference as normal
values of ICAM-1 and E-selectin were detected in these
samples using assays of similar design. Similar levels of
VCAM-1 were detected in repeat samples 2 months later.
The cellular source of the circulating adhesion molecules is
unclear. E-selectin is restricted exclusively to activated
endothelial cells and is present on the endothelium of blood
vessels in many tumours, particularly Hodgkin's and T cell
lymphomas, with only weak expression in B cell lymphomas
and solid tumours (Ruco & Gearing, 1991; Ruco et al.,
1992). Solid tumours in which ulceration occurs show strong
expression of E-selectin. VCAM-1, whilst largely present on
activated endothelial cells, is also present on dendritic cells,
neuronal cells and renal parietal epithelium (Rice et al., 1991),
and in lymphoid malignancies shows a similar pattern of
expression to that of E-selectin (Ruco et al., 1992). ICAM-1,
which is elevated to a greater extent and in a greater propor-
tion of these cancer patients, has a much wider cellular
distribution (Smith & Thomas, 1990) and in addition to
endothelial cells has been described on normal and malignant
epithelial tissue including melanoma cell lines and primary
tissue, renal cell lines and intestinal cell lines (Natali et al.,
1990; Tomita et al., 1990; Becker et al., 1991). Thus at least
some of the soluble ICAM-1 present in sera of cancer
patients is probably derived from tumour tissue. Using an
ELISA which is specific for human ICAM-1, we have dem-
onstrated that human melanoma cells will release soluble
ICAM-1 into the serum of nude mice (Giavazzi et al., 1992).
The differences in the findings with regard to E-selectin,
VCAM-1 and ICAM-1 probably reflect differences in source,
kinetics of expression or destruction, and possibly signals
inducing their expression and/or release. Both E-selectin and
VCAM-1 are induced by TNF-a or IL-1l3 with E-selectin
expression being further increased by y-interferon whereas
that of VCAM-1 can be further increased by y-interferon or
IL-4 (Doukas & Pober 1990; Thornhill et al., 1991,
Masinowsky et al., 1990). ICAM-1 expression has been
reported to be increased by IL-1, '- and P-interferon, TNF-o,
IL-4, IL-6 and IL-2 (Giavazzi et al., 1992; Buckle & Hogg,
1990; Valent et al., 1991), with effects being tissue-dependent.
Whether the cytokines responsible for inducing adhesion
molecule expression and shedding are tumour-derived or
derived from surrounding host tissue is a matter for specula-
tion, and the mechanism underlying shedding of adhesion
molecules is not yet understood. IL-1 and TNF both cause
the release of ICAM-1, VCAM-1 and E-selectin from human
umbilical vein endothelial cells (Pigott et al., 1992). Gamma-
interferon induces expression and shedding of ICAM-1 from
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gastric cancer cell lines (Harning et al., 1991) and IL-1,
TNF-x and y-IFN but not IL-6 induced shedding of ICAM-1
from melanoma cell lines (Becker et al., 1991, Giavazzi et al.,
1992).
The significance of adhesion molecule shedding is not clear
but it may have profound implications for tumour metas-
tasis. Shedding of ICAM-1 by circulating tumour cells may
allow their escape from surveillance by cytotoxic T cells and
natural killer cells and thus promote metastasis. Conversely
shedding of adhesion molecules by activated endothelial cells
may possibly serve to 'block' counterligands, for example on
tumour cells, and subsequently prevent their adhesion to
endothelial cells at metastatic sites. Future studies will
include the longitudinal and cross-sectional studies of soluble
adhesion molecules in patient groups and will examine the
clinical utility of such measurements in patient management
and prognosis. This approach, together with laboratory
investigations into the mechanism of adhesion molecule shed-
ding, may provide an insight into the possible role of
cytokines and adhesion molecules in tumour progession.
R.E.B., T.P. and P.J.S. are grateful to the Yorkshire Cancer
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